Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 87
Tirzepatide and metformin for PCOS: RCT
A 60-patient Chinese trial found tirzepatide 5 mg plus metformin cut weight by 10.4 kg in 16 weeks for women with PCOS, six times more than metformin alone.
TOGETHER-PsA: tirzepatide plus ixekizumab
A Phase 3b trial finds that adding tirzepatide to ixekizumab improves joint disease and weight in psoriatic arthritis patients with obesity.
GLP-1 drugs in teens: what youth say
A qualitative study of 29 adolescents on GLP-1 and other weight-loss drugs finds families are positive about treatment but uncertain about when to stop.
Peptide blood work: which labs to request
IGF-1, fasting glucose, HbA1c, lipid panel, CMP, CBC, and thyroid markers. Here is what each one tracks and why your clinician may want it.
Why patients stop GLP-1 drugs, and restart
A narrative review in Diabetes, Obesity & Metabolism examines GLP-1 RA discontinuation rates, reasons, and weight-regain patterns after stopping.
GLP-1 drugs and severe GI motility risk
A 626,000-person cohort study found GLP-1 therapies carry a 37% higher relative risk of severe GI events versus SGLT-2 inhibitors.
Tirzepatide and ketoacidosis: FAERS signal
A FAERS analysis flags starvation ketoacidosis as a post-marketing signal for tirzepatide. Here is what the numbers say.
Tirzepatide and MASLD: a mouse study
A mouse study ties tirzepatide's liver effect in MASLD to the CCL2/CCR2 axis, adding mechanistic detail to SYNERGY-NASH.
Tirzepatide in Smith-Magenis syndrome
A JCEM case report found 9.4% weight loss and reduced aggression in a patient with Smith-Magenis syndrome on tirzepatide 5 mg weekly.
Tirzepatide after bariatric surgery
An Italian study reports 18.1% weight loss at 24 weeks in 34 post-bariatric patients on tirzepatide. Early data, small sample.
GLP-1 constipation: prevalence vs incidence
A 2026 study argues many GLP-1 users had constipation before starting treatment, inflating the headline rate.
GLP-1 drugs and fewer knee replacements
A database study of over 42,000 patients links GLP-1 receptor agonist use to significantly lower rates of knee replacement surgery.